CGON241220P55000
- 0.00
- 0.000.00%
CG Oncology Newsroom
One CG Oncology Insider Has Reduced Their Stake
Express News | CG Oncology To Present At Society of Urologic Oncology (SUO) 25th Annual Meeting Dec. 4-6
CG Oncology's Financial Results and Clinical Developments
RBC Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $66
Analysts Offer Insights on NA Companies: CG Oncology, Inc. (CGON), Smith Douglas Homes Corp. Class A (SDHC) and Palmer Square Capital BDC Inc. (PSBD)
CG Oncology | 10-Q: Q3 2024 Earnings Report
CG Oncology | 8-K: CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
CG Oncology 3Q Loss/Shr 30c >CGON
CG Oncology 3Q Loss $20.4M >CGON
CG Oncology Reports Q3 EPS (30c), Consensus (37c)
Express News | CG Oncology Inc : Qtrly Shr Loss $0.30
Express News | CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
H.C. Wainwright Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $75
CG Oncology Price Target Maintained With a $75.00/Share by HC Wainwright & Co.
CG Oncology's Strategic Growth and Promising Therapeutic Developments Reinforce Buy Rating
CG Oncology Announces Nature Medicine Publication Of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec In Combination With Nivolumab In Muscle-Invasive Bladder Cancer
Morgan Stanley Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $55
UBS Launches SMID Cap Biotechs With Cancer, Autoimmunity in Focus
This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
CG Oncology Analyst Ratings